美国食品和药物管理局批准的抗体药物共轭物的眼毒性。

IF 1.6 4区医学 Q3 OPHTHALMOLOGY

Cutaneous and Ocular Toxicology Pub Date : 2024-10-18 DOI:10.1080/15569527.2024.2408677

Shaurey Vetsa, Stephanie Zhang, Walker Kay, Neil Kelkar, Arko Ghosh, Suhail Alam, Phillip C Hoopes, Majid Moshirfar

{"title":"美国食品和药物管理局批准的抗体药物共轭物的眼毒性。","authors":"Shaurey Vetsa, Stephanie Zhang, Walker Kay, Neil Kelkar, Arko Ghosh, Suhail Alam, Phillip C Hoopes, Majid Moshirfar","doi":"10.1080/15569527.2024.2408677","DOIUrl":null,"url":null,"abstract":"Antibody-drug conjugates (ADCs) are an emerging field of cancer treatments that are becoming more widespread in their use. However, there are potential ocular toxicities associated with these drugs that ophthalmologists need to be aware of to better maintain ocular health as patients undergo rigorous medical treatment for their conditions. While many ADCs have been approved by the Food and Drug Administration (FDA), many subsequent reports have been published regarding additional ocular side effects these drugs may cause. This review provides ophthalmologists with a practical guide on how to treat ocular toxicities associated with all FDA-approved ADCs to date. The potential pathophysiology of side effects is also discussed.","PeriodicalId":11023,"journal":{"name":"Cutaneous and Ocular Toxicology","volume":" ","pages":"1-12"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ocular toxicities of FDA-approved antibody drug conjugates.\",\"authors\":\"Shaurey Vetsa, Stephanie Zhang, Walker Kay, Neil Kelkar, Arko Ghosh, Suhail Alam, Phillip C Hoopes, Majid Moshirfar\",\"doi\":\"10.1080/15569527.2024.2408677\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antibody-drug conjugates (ADCs) are an emerging field of cancer treatments that are becoming more widespread in their use. However, there are potential ocular toxicities associated with these drugs that ophthalmologists need to be aware of to better maintain ocular health as patients undergo rigorous medical treatment for their conditions. While many ADCs have been approved by the Food and Drug Administration (FDA), many subsequent reports have been published regarding additional ocular side effects these drugs may cause. This review provides ophthalmologists with a practical guide on how to treat ocular toxicities associated with all FDA-approved ADCs to date. The potential pathophysiology of side effects is also discussed.\",\"PeriodicalId\":11023,\"journal\":{\"name\":\"Cutaneous and Ocular Toxicology\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cutaneous and Ocular Toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15569527.2024.2408677\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cutaneous and Ocular Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15569527.2024.2408677","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

抗体药物共轭物（ADC）是一种新兴的癌症治疗方法，其应用越来越广泛。然而，这些药物可能会对眼部产生毒性，眼科医生需要注意，以便在患者接受严格的药物治疗时更好地维护眼部健康。虽然许多 ADC 已获得美国食品和药物管理局 (FDA) 批准，但随后又发表了许多关于这些药物可能导致其他眼部副作用的报告。本综述为眼科医生提供了一份实用指南，指导他们如何治疗与迄今为止所有经 FDA 批准的 ADC 相关的眼部毒性反应。此外，还讨论了副作用的潜在病理生理学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ocular toxicities of FDA-approved antibody drug conjugates.

Antibody-drug conjugates (ADCs) are an emerging field of cancer treatments that are becoming more widespread in their use. However, there are potential ocular toxicities associated with these drugs that ophthalmologists need to be aware of to better maintain ocular health as patients undergo rigorous medical treatment for their conditions. While many ADCs have been approved by the Food and Drug Administration (FDA), many subsequent reports have been published regarding additional ocular side effects these drugs may cause. This review provides ophthalmologists with a practical guide on how to treat ocular toxicities associated with all FDA-approved ADCs to date. The potential pathophysiology of side effects is also discussed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cutaneous and Ocular Toxicology 医学-毒理学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

1 months

期刊介绍： Cutaneous and Ocular Toxicology is an international, peer-reviewed journal that covers all types of harm to cutaneous and ocular systems. Areas of particular interest include pharmaceutical and medical products; consumer, personal care, and household products; and issues in environmental and occupational exposures. In addition to original research papers, reviews and short communications are invited, as well as concise, relevant, and critical reviews of topics of contemporary significance.